Remediation and Response Services 

ProPharma combines deep industry knowledge with a personalized approach to ensure your compliance efforts are effective, timely, and aligned with regulatory expectations.

Ensure Regulatory Compliance with ProPharma's Remediation and Response Services

Document search icon

Regulatory Agency Response Services

Regulatory Agency Response Services

Checkmark icon

Comprehensive Compliance Assessments

Comprehensive Compliance Assessments

Pin leading to another pin icon

Strategic Remediation Planning

Strategic Remediation Planning

Service icon

Remediation Implementation Support

Remediation Implementation Support

When your company receives observations, a Form 483, or a Warning Letter from the FDA or another regulatory agency, a timely and thorough response is crucial. ProPharma's Regulatory Agency Response Services are designed to help you navigate this complex process with confidence and precision.

Before drafting your response, it’s essential to step back and form a comprehensive plan of action. Our experts assist you in developing a structured and strategic plan to address the regulatory findings effectively. This involves understanding the regulatory observations in detail, prioritizing the issues based on their severity and potential impact, and outlining the steps needed to address each one.

Business Professionals pointing at papers with their fingers

When the FDA or other regulatory agency identifies observations and areas for improvement, it is important for the company to conduct a thorough assessment of all GxP systemsTo ensure objectivity and accuracy, we recommend seeking the help of third-party experts to conduct independent assessments. At ProPharma, we will validate the observations noted by the regulatory agency, ensuring a complete understanding of the issues and their root causes. We proactively identify other potential compliance risks across your systems, facilities, and processes. This comprehensive approach helps prevent future regulatory issues and promotes overall operational excellence. 

Business worker collaborating around a blackboard

ProPharma's strategic remediation planning services provide a comprehensive roadmap to address regulatory findings and ensure long-term compliance. Effective remediation requires more than just addressing immediate concerns; it involves developing a strategic plan that ensures sustainable compliance and continuous improvement. Our strategic remediation planning services help you navigate this complex process with precision and foresight. 

pre-ind-meeting-planning

The transition from planning to implementation is critical to the success of any remediation effort. ProPharma’s Remediation Implementation Support services are designed to guide you through this process, ensuring that corrective and preventive actions are executed effectively and efficiently. ProPharma's Remediation Implementation Support services ensure the successful execution of your strategic remediation plan, driving compliance and operational excellence across your organization.

Our team of quality and compliance experts provides hands on support and comprehensive guidance on navigating the complexities of GxP compliance. Whether you need support with Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), or other GxP standards, ProPharma can provide you with industry experts equipped to address your specific needs. With extensive experience across almost every facet of healthcare, our team has completed thousands of projects, delivering compliant and effective solutions tailored to your unique challenges.

Row of customer service professionals wearing headset one person smiling at camera

Expert Guidance for Your Compliance Needs

Ensure your organization meets regulatory standards with a comprehensive, expert-led approach to remediation. Connect with our specialists today to develop a tailored plan that addresses your compliance challenges effectively and efficiently.

Several business professionals working around a conference table

Regulatory Agency Response Services

ProPharma's expert team collaborates closely with your organization to drive effective remediation and regulatory response strategies.

Assemble an Action Team:
We assemble an action team of internal and external experts, led by ProPharma's seasoned professionals, to ensure a compliant remediation process. We recommend that you involve key personnel from Management, Quality Assurance, Operations, Compliance, and Regulatory Affairs. 

Draft the Response:
ProPharma's experts draft a clear and comprehensive response to regulatory agencies by:

  • Addressing Each Observation: Explaining corrective actions with specific timelines.
  • Root Cause Analysis: Summarizing investigations into the root causes.
  • Corrective and Preventive Actions (CAPA): Outlining a plan to correct current issues and prevent recurrence.

Monitor and Follow-Up:
After submitting your response, it’s important to monitor the implementation of corrective actions and ensure their effectiveness. ProPharma assists in: 

  • Tracking Progress: Regularly reviewing remediation efforts to ensure timely completion.
  • Evaluating Effectiveness Checks: Verifying executed actions were successful to prevent recurrence.
  • Continuous Improvement: Identifying opportunities to enhance compliance and operational excellence.
  • Verifying Supporting Documentation: Evaluating documentation to ensure evidence is sufficient to support your response. 
person-signing-document
Hand writing on paper

Comprehensive Compliance Assessments

We start with a detailed assessment of your facility, processes, and documentation to confirm agency findings and identify additional non-compliance areas. Our experts review your quality management systems, manufacturing practices, and operational procedures, identifying gaps against regulatory requirements and industry best practices.

Beyond addressing cited issues, we proactively identify related problems across systems, facilities, or production lines to prevent recurrence and demonstrate systemic resolution.

Understanding the root causes of deficiencies is crucial. We conduct in-depth investigations using root cause analysis techniques to address system weaknesses, procedural lapses, or human errors, ensuring long-term compliance.

We prioritize findings based on their severity, impact on product quality, and regulatory implications, providing clear recommendations for a structured and efficient remediation process.

A comprehensive report, including findings, root cause analysis, and a prioritized action plan, is provided as a roadmap for your remediation efforts, ensuring clear and actionable steps toward regulatory compliance.

Strategic Remediation Planning

We partner with your team to develop a comprehensive plan to address your remediation activities:

  • Understanding Regulatory Observations: Thoroughly reviewing each observation and inspection report, and engaging with your stakeholders to ensure accurate interpretation.
  • Prioritizing Issues: Helping prioritize compliance gaps based on their severity, impact on product quality, and regulatory implications, ensuring critical concerns are addressed first.
  • Outlining CAPA: Developing a detailed Corrective and Preventive Actions (CAPA) plan for each issue, specifying actions, responsible personnel, and timelines for implementation.
  • Proposed Timelines: Providing realistic timelines for each corrective action, ensuring a structured and time-bound remediation process.
  • Integrating Continuous Improvement: Incorporating continuous improvement practices into your quality management systems for proactive compliance and operational excellence.
Project manager reviewing project plans and timelines in an office
Professional business people collaborating at a conference table

Expert Project Management

ProPharma’s project managers oversee the remediation process, coordinating activities, meeting timelines, and optimizing resources. We provide ongoing support and regular progress updates, addressing potential delays and proposing solutions to keep the project on track.

Regulatory Action Types

European Medicines Agency (EMA)

Warning Types:
  • Non-Conformance Report (NCR)
  • Inspection Report
  • Statement of Non-Compliance
  • Suspension/Withdrawal of Marketing Authorization 
  • CAPA Request (Corrective...
Read More

European Medicines Agency (EMA)

Warning Types:
  • Non-Conformance Report (NCR)
  • Inspection Report
  • Statement of Non-Compliance
  • Suspension/Withdrawal of Marketing Authorization 
  • CAPA Request (Corrective and Preventive Actions)
Read Less

Medicines and Healthcare products Regulatory Agency (MHRA)

Warning Types:

  • Inspection Action Group (IAG) Meeting
  • Compliance Notice
  • Improvement Notice or Regulatory Action
  • Non-Compliance Report

Medicines and Healthcare products Regulatory Agency (MHRA)

Warning Types:

  • Inspection Action Group (IAG) Meeting
  • Compliance Notice
  • Improvement Notice or Regulatory Action
  • Non-Compliance Report
Read Less
Thumbnail Image for ProPharma Supports a Contract Manufacturer's Form 483 Response

News & Insights

Pros and Cons of Working with a CRO

July 31, 2025

Pros and Cons of Working with a CRO

Explore the pros and cons of working with a Contract Research Organization (CRO) and how ProPharma sets a new standard in clinical development success.

Understanding PADER: A Key Pharmacovigilance Requirement for the U.S. Market

July 28, 2025

Understanding PADER: A Key Pharmacovigilance Requirement for the U.S. Market

Learn about PADER, a crucial pharmacovigilance requirement for U.S. drug safety monitoring, and how it differs from PSUR in ensuring compliance and patient safety. Summarizing the main point of the...

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guide for Marketing Authorization Holders (MAHs)

July 25, 2025

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guid...

Learn about the crucial roles of QPPV, LPPV, and PSMF in ensuring effective pharmacovigilance and regulatory compliance for Marketing Authorization Holders (MAHs).

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Successfully Executing a Tech Transfer in a Week - ProPharma

July 29, 2025

Successfully Executing a Tech Transfer in a Week

Discover how ProPharma supported a $3B pharmaceutical tech transfer that was executed in just 3 days, relocating five complex product lines. The plan included FDA alignment, pre-approved protocols,...

Case Study Obesity – Accelerated Timelines - ProPharma

July 29, 2025

Obesity – Accelerated Timelines

A mid-size biotech needed fast U.S. market entry for an obesity trial. ProPharma activated 20 sites in 30 days and enrolled 300+ patients—meeting goals despite an increased sample size. Strategic...

Whitepapers Key Compliance Challenges in U.S. Medical Information Services - ProPharma

July 29, 2025

Key Compliance Challenges in U.S. Medical Information Services

For Medical Information (MI) teams navigating today’s evolving regulatory landscape, compliance isn’t just a requirement — it’s a strategic imperative. From managing off-label inquiries to...

Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

News & Insights

Pros and Cons of Working with a CRO

July 31, 2025

Pros and Cons of Working with a CRO

Explore the pros and cons of working with a Contract Research Organization (CRO) and how ProPharma sets a new standard in clinical development success.

Understanding PADER: A Key Pharmacovigilance Requirement for the U.S. Market

July 28, 2025

Understanding PADER: A Key Pharmacovigilance Requirement for the U.S. Market

Learn about PADER, a crucial pharmacovigilance requirement for U.S. drug safety monitoring, and how it differs from PSUR in ensuring compliance and patient safety. Summarizing the main point of the...

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guide for Marketing Authorization Holders (MAHs)

July 25, 2025

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guid...

Learn about the crucial roles of QPPV, LPPV, and PSMF in ensuring effective pharmacovigilance and regulatory compliance for Marketing Authorization Holders (MAHs).

Previous Post Arrow Next Post Arrow
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Successfully Executing a Tech Transfer in a Week - ProPharma

July 29, 2025

Successfully Executing a Tech Transfer in a Week

Discover how ProPharma supported a $3B pharmaceutical tech transfer that was executed in just 3 days, relocating five complex product lines. The plan included FDA alignment, pre-approved protocols,...

Case Study Obesity – Accelerated Timelines - ProPharma

July 29, 2025

Obesity – Accelerated Timelines

A mid-size biotech needed fast U.S. market entry for an obesity trial. ProPharma activated 20 sites in 30 days and enrolled 300+ patients—meeting goals despite an increased sample size. Strategic...

Whitepapers Key Compliance Challenges in U.S. Medical Information Services - ProPharma

July 29, 2025

Key Compliance Challenges in U.S. Medical Information Services

For Medical Information (MI) teams navigating today’s evolving regulatory landscape, compliance isn’t just a requirement — it’s a strategic imperative. From managing off-label inquiries to...

Previous Resource Arrow Next Resource Arrow
Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

Previous Webinar Arrow Next Webinar Arrow